Wedbush Upgrades Black Diamond Therapeutic to Outperform, Announces $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Robert Driscoll upgraded Black Diamond Therapeutic (NASDAQ:BDTX) from Neutral to Outperform and announced a $10 price target.
June 27, 2023 | 3:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Black Diamond Therapeutic (NASDAQ:BDTX) has been upgraded from Neutral to Outperform by Wedbush analyst Robert Driscoll, with a new price target of $10.
The upgrade from Neutral to Outperform by Wedbush analyst Robert Driscoll indicates a positive outlook for Black Diamond Therapeutic. The new price target of $10 suggests potential upside for the stock, which may lead to short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100